- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Canabo Medical (TSXV:CMM) has announced it has opened its 15th clinic in London, Ontario. As quoted in the press release: Canabo is also pleased to announce that Dr. Neil Smith, Executive Chairman will be presenting results from the Company’s Observational Study at the Canadian Consortium for the Investigation of Cannabinoids (CCIC) “Cannabinoids in Clinical Practice” …
Canabo Medical (TSXV:CMM) has announced it has opened its 15th clinic in London, Ontario.
As quoted in the press release:
Canabo is also pleased to announce that Dr. Neil Smith, Executive Chairman will be presenting results from the Company’s Observational Study at the Canadian Consortium for the Investigation of Cannabinoids (CCIC) “Cannabinoids in Clinical Practice” event April 6-7, 2017 in Toronto. The research to be presented will focus on observations of benzodiazepine use among Canabo patients. The Company currently tracks over 1,500 patients who started medical cannabinoids while on benzodiazepines.
Dr. Smith stated, “We consider the release of this first research report a milestone not just for Canabo but for the medical cannabis industry as a whole. We anticipate that the results of our first study will be significant within the medical community as a large number of patients under our treatments completely eliminated benzodiazepines from their medication regime.”
Click here to read the full press release.
Source: www.canabocorp.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.